Filtered By:
Condition: Brain Tumor
Procedure: Transplants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
In this research, we analyze a relationship between CD44 expression and responsiveness to Bev and elucidate the role of CD44 in anti ‐VEGF therapy. These results indicate CD44 will be a useful biomarker for predicting responsiveness to bevacizumab and may serve as a therapeutic target in both primary and recurrent GBMs. AbstractAntiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy....
Source: Cancer Medicine - February 5, 2021 Category: Cancer & Oncology Authors: Masahiro Nishikawa,
Akihiro Inoue,
Takanori Ohnishi,
Hajime Yano,
Yonehiro Kanemura,
Shohei Kohno,
Shiro Ohue,
Saya Ozaki,
Shirabe Matsumoto,
Satoshi Suehiro,
Yawara Nakamura,
Seiji Shigekawa,
Hideaki Watanabe,
Riko Kitazawa,
Junya Tanaka,
Tags: ORIGINAL RESEARCH Source Type: research
Regulation of temozolomide resistance in glioma cells via the RIP2/NF- κB/MGMT pathway.
CONCLUSION: We report that the RIP2/NF-κB/MGMT signaling pathway is involved in the regulation of TMZ resistance. Interference with NF-κB or MGMT activity could constitute a novel strategy for the treatment of RIP2-positive TMZ-resistant glioma.
PMID: 33460245 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - January 18, 2021 Category: Neuroscience Authors: Hu YH, Jiao BH, Wang CY, Wu JL Tags: CNS Neurosci Ther Source Type: research
miR-452 promotes the development of gastric cancer via targeting EPB41L3
In this study, we found that miR-452 was highly expressed in both tumor tissue and gastric cancer cells, and could directly target the cancer suppressor gene EPB41L3 3′-UTR. miR-452 significantly promoted the proliferation, migration and the S-phase arrest of gastric cancer cells, but EPB41L3 as a downstream target gene of miR-452 reversed such promoting effect. While down-regulation of miR-452 expression significantly inhibited the malignant biological behavior of gastric cancer cells, but this inhibitory effect was reversed by EPB41L3 siRNA. In addition, miR-452 in the gastric cancer xenograft model in nude mice could ...
Source: Pathology Research and Practice - November 1, 2019 Category: Pathology Source Type: research
Down-regulation of STIP1 regulate apoptosis and invasion of glioma cells via TRAP1/AKT signaling pathway
ConclusionsSTIP1 is highly expressed in glioblastoma compared to normal brain tissues. Downregulation of STIP1 in glioma cells reduces cell proliferation rate and invasion and increases cell apoptosis.
Source: Cancer Genetics - June 4, 2019 Category: Cancer & Oncology Source Type: research
